MANKIND PHARMA
Back to Balance Sheet
|
MANKIND PHARMA Last 5 Year Contingent Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹89 Cr | ₹48 Cr | ₹83 Cr | ₹35 Cr | ₹242 Cr |
What is the latest Contingent Liabilities ratio of MANKIND PHARMA ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹89 Cr |
Mar2023 | ₹48 Cr |
Mar2022 | ₹83 Cr |
Mar2021 | ₹35 Cr |
Mar2020 | ₹242 Cr |
How is Contingent Liabilities of MANKIND PHARMA Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹89 Cr | 85.77 | |
Mar2023 | ₹48 Cr | -41.97 | |
Mar2022 | ₹83 Cr | 137.32 | |
Mar2021 | ₹35 Cr | -85.60 | |
Mar2020 | ₹242 Cr | - |
Compare Contingent Liabilities of peers of MANKIND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
MANKIND PHARMA | ₹103,524.9 Cr | 0.6% | 3.1% | 34.4% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹422,271.0 Cr | -0.9% | -4.8% | 50.2% | Stock Analytics | |
DIVIS LABORATORIES | ₹161,183.0 Cr | 3% | 5.9% | 65% | Stock Analytics | |
CIPLA | ₹120,605.0 Cr | 1.5% | 0.1% | 19.9% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹100,869.0 Cr | -0.4% | -8.2% | 7.1% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,808.6 Cr | 0.6% | -5.3% | 51% | Stock Analytics |
MANKIND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
MANKIND PHARMA | 0.6% |
3.1% |
34.4% |
SENSEX | 3.5% |
-0.1% |
21.9% |
You may also like the below Video Courses